Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

被引：0
|
作者：
A F List
J M Bennett
M A Sekeres
B Skikne
T Fu
J M Shammo
S D Nimer
R D Knight
A Giagounidis
机构：
来源：
Leukemia | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Leukemia (2014) 28, 1033–1040; doi:10.1038/leu.2013.305 Since the publication of this article it has been noted that there was an omission in the listing of conflict of interest. JM Bennett was listed as having no conflict of interest; however, the authors would like to correct this to read:
引用
收藏
页码：2452 / 2452
相关论文
共 50 条
  • [41] Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis
    Sekeres, M.
    Swern, A.
    Fenaux, P.
    Greenberg, P.
    Sanz, G.
    Bennett, J.
    Dreyfus, F.
    Cazzola, M.
    List, A.
    Garcia-Manero, G.
    Li, J. Shiansong
    Sugrue, M.
    LEUKEMIA RESEARCH, 2013, 37 : S69 - S70
  • [42] Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)
    Almeida, Antonio
    Santini, Valeria
    Croepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Mufti, Ghulam J.
    Sanz, Guillermo
    Skikne, Barry
    Hoenekopp, Albert
    Seguy, Francis
    Zhong, Jianhua
    Fenaux, Pierre
    BLOOD, 2015, 126 (23)
  • [43] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
  • [44] TREATMENT OF LOWER RISK MDS WITH DEL 5Q WITH LENALIDOMIDE (LEN): CURRENT RESULTS OF THE FRENCH PATIENT NAMED PROGRAM (ATU)
    Le Bras, E.
    Sebert, M.
    Eclache, V.
    Lamy, T.
    Dlaunay, J.
    Visanica, S.
    Dreyfus, E.
    Banos, A.
    Blanc, M.
    Leyronnas, C.
    Besson, C.
    Derenzis, B.
    Thomas, X.
    Rodon, C.
    Vey, N.
    Gardernbas, M.
    Faron, M.
    Bauduer, F.
    Ramee, J. E.
    Zajec, D.
    Delmer, A.
    Rea, D.
    Beyne-Rauzy, O.
    Ceccaldi, J.
    Beaucournou, P.
    Dugay, J.
    Fenaux, P.
    Ades, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 96 - 96
  • [45] The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    Buckstein, Rena
    Beach, C. L.
    Guo, Shien
    Altincatal, Arman
    Wu, Chengqing
    Fenaux, Pierre
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (02): : 136 - +
  • [46] TELOMERE SHORTENING AND AML PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND DELETION 5Q TREATED WITH LENALIDOMIDE
    Goehring, G.
    Lange, K.
    Hofmann, W.
    Buesche, G.
    Kreipe, H.
    Hellstroem-Lindberg, E.
    Giagounidis, A.
    Schlegelberger, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 378 - 379
  • [47] MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q)
    Santini, V.
    Li, J. S.
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S59 - S59
  • [48] CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY
    Santini, V.
    Li, J. Shiansong
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Sanna, A.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 3 - 4
  • [49] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Butrym, Aleksandra
    Lech-Maranda, Ewa
    Patkowska, Elzbieta
    Kumiega, Beata
    Bieniaszewska, Maria
    Mital, Andrzej
    Madry, Krzysztof
    Torosian, Tigran
    Wichary, Ryszard
    Rybka, Justyna
    Warzocha, Krzysztof
    Mazur, Grzegorz
    BMC CANCER, 2015, 15
  • [50] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Aleksandra Butrym
    Ewa Lech-Maranda
    Elżbieta Patkowska
    Beata Kumiega
    Maria Bieniaszewska
    Andrzej Mital
    Krzysztof Madry
    Tigran Torosian
    Ryszard Wichary
    Justyna Rybka
    Krzysztof Warzocha
    Grzegorz Mazur
    BMC Cancer, 15
12345